Our nanocomplex approach (ie, AuNPs with transferrin-like peptides attached), seeks to exploit the upregulated transferrin receptor on GBM cells, thereby improving the specificity of drug delivery and minimizing off-target effects [12]. This evidence concerns the gene TFRC and glioblastoma.